deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03915769

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Sponsor: Celgene

Conditions Colitis, Ulcerative
Interventions Ozanimod Placebo
Updated 25 times since 2019 Last updated: Oct 13, 2025 Started: Jun 3, 2019 Primary completion: Sep 30, 2025 Completion: Sep 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colitis, Ulcerative, this trial is completed. The trial is conducted by Celgene and has accumulated 25 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2022 · 13 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. May 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 20 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  5. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Nov 2022 — Mar 2023 [monthly]

    Recruiting PHASE3

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  9. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  10. Mar 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  11. Feb 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

  12. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  13. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  14. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  15. May 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  16. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE3

  17. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  18. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  19. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting · Phase: PHASE2_PHASE3 → PHASE3

  20. May 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abiko, Japan , Aki-gun, Japan , Bunkyo-ku, Japan , Chikushino-shi, Japan , Fujiidera, Japan , Fukui, Japan , Fukuoka, Japan , Gifu, Japan , Hakodate, Japan , Hirosaki, Japan and 45 more locations